Concepedia

Author

Jonathan Q. Tran

Biogen (United States)ORCID

Also Known As

J Q Tran, J TRAN, J Tran, J. Q. Tran, J. Tran, J.Q. Tran, Jonathan Q Tran, Jonathan Q. Tran, Jonathan Tran

47

Publications

1.3K

Citations

20

H-Index

49

Concepts

All Affiliations

Biogen (United States)Cairo UniversityLa Roche CollegeAbbVie (United States)Bristol-Myers Squibb (Switzerland)
JQ

About

Jonathan Q. Tran is an author at Biogen (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

15

552

2

Hepatology

3

3

94

3

Endocrinology

2

2

147

4

Health Sciences

1

1

22

5

Emergency Medicine

1

1

35

Jonathan Q. Tran

×

29

Publications

1.2K

Citations

20

H-Index

YearCitations

In Vitro Antiviral Activity and Single-Dose Pharmacokinetics in Humans of a Novel, Orally Bioavailable Inhibitor of Human Rhinovirus 3C Protease

Amy K. Patick, Mary A. Brothers, Fausto Maldonado,

Antimicrobial Agents and Chemotherapy

2005

133

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

Jonathan Q. Tran, Jitesh Rana, Frederik Barkhof,

Neurology Neuroimmunology & Neuroinflammation

2014

121

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Jonathan Q. Tran, Jeffrey Hartung, Robert Peach,

The Journal of Clinical Pharmacology

2017

106

Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction.

Jonathan Q. Tran, Steven J. Kovacs, Thomas McIntosh,

PubMed

1999

78

Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator

Sekhar Surapaneni, Usha Yerramilli, April Bai,

Drug Metabolism and Disposition

2021

70

Morning Spot and 24‐Hour Urinary 6β‐Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction

Jonathan Q. Tran, Steven J. Kovacs, Thomas McIntosh,

The Journal of Clinical Pharmacology

1999

69

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

Jonathan Q. Tran, Jeffrey Hartung, Allan Olson,

Clinical Pharmacology in Drug Development

2017

58

Assessment of the Potential Pharmacokinetic and Pharmacodynamic Interactions between Erythromycin and Argatroban

Jonathan Q. Tran, Robert A. Di Cicco, Sunita B. Sheth,

The Journal of Clinical Pharmacology

1999

54

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

Edward Gane, Catherine Stedman, Alicja Wiercińska‐Drapało,

Journal of Hepatology

2011

48

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS

Sarah Harris, Jonathan Q. Tran, Harry Southworth,

Neurology Neuroimmunology & Neuroinflammation

2020

35

Page 1